4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
| Status: | Recruiting |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 2/22/2019 |
| Start Date: | June 25, 2018 |
| End Date: | June 17, 2019 |
| Contact: | Pfizer CT.gov Call Center |
| Email: | ClinicalTrials.gov_Inquiries@pfizer.com |
| Phone: | 1-800-718-1021 |
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF-06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants
will receive an investigational product or placebo for 28 days.
will receive an investigational product or placebo for 28 days.
Inclusion Criteria:
- Type 2 diabetes treated with a stable dose of metformin at least 500 mg
- HbA1c value between 7.0 and 10.5%
Exclusion Criteria:
- Type 1 diabetes or secondary forms of diabetes
We found this trial at
3
sites
Anaheim Clinical Trials, LLC Anaheim Clinical Trials (ACT) is a research center of excellence for...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials